Perspective Book Value Per Share vs Free Cash Flow Yield Analysis

CATX Stock

3.65 0.12 3.18%

Perspective Therapeutics financial indicator trend analysis is much more than just breaking down Perspective Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Perspective Therapeutics is a good investment. Please check the relationship between Perspective Therapeutics Book Value Per Share and its Free Cash Flow Yield accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Perspective Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.

Book Value Per Share vs Free Cash Flow Yield

Book Value Per Share vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Perspective Therapeutics Book Value Per Share account and Free Cash Flow Yield. At this time, the significance of the direction appears to have pay attention.

The correlation between Perspective Therapeutics' Book Value Per Share and Free Cash Flow Yield is -1.0. Overlapping area represents the amount of variation of Book Value Per Share that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Perspective Therapeutics, assuming nothing else is changed. The correlation between historical values of Perspective Therapeutics' Book Value Per Share and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Book Value Per Share of Perspective Therapeutics are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Book Value Per Share i.e., Perspective Therapeutics' Book Value Per Share and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-1.0

Relationship Direction	Negative
Relationship Strength	Strong

View All Relationships

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Perspective Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Perspective Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Perspective Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.At this time, Perspective Therapeutics' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 15.35 in 2024, whereas Tax Provision is likely to drop (2.5 M) in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	18.2M	17.4M	42.4M	44.5M
Cost Of Revenue	6.2M	5.5M	4.9M	4.2M

Total Operating Expenses Cost Of Revenue

Perspective Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Good Will	Non Currrent Assets Other	Other Assets
Total Assets		0.6	0.75	0.82	0.99	0.76	-0.24	-0.48	-0.87	0.82	0.52	0.78	0.53	0.33	0.15	0.79	0.91	0.78	0.96	0.81	0.57	-0.34	0.96	0.42	-0.09	0.86
Short Long Term Debt Total	0.6		0.96	0.93	0.48	0.83	-0.1	0.31	-0.66	0.92	-0.27	0.96	-0.34	-0.13	-0.3	0.96	0.5	0.64	0.62	0.94	-0.3	-0.75	0.74	0.34	-0.01	0.54
Other Current Liab	0.75	0.96		0.98	0.64	0.88	-0.04	0.13	-0.72	0.97	-0.09	0.99	-0.15	-0.11	-0.32	0.98	0.66	0.72	0.73	0.98	-0.11	-0.75	0.85	0.29	0.03	0.71
Total Current Liabilities	0.82	0.93	0.98		0.72	0.9	-0.06	0.07	-0.8	1.0	-0.02	0.99	-0.05	0.0	-0.17	0.99	0.74	0.82	0.81	1.0	0.0	-0.71	0.91	0.31	-0.1	0.78
Total Stockholder Equity	0.99	0.48	0.64	0.72		0.68	-0.26	-0.6	-0.84	0.73	0.63	0.67	0.65	0.4	0.23	0.69	0.9	0.72	0.94	0.71	0.69	-0.22	0.92	0.42	-0.08	0.84
Property Plant And Equipment Net	0.76	0.83	0.88	0.9	0.68		-0.13	-0.03	-0.76	0.9	0.08	0.89	0.0	0.24	-0.17	0.9	0.8	0.73	0.75	0.9	0.05	-0.59	0.85	0.35	-0.09	0.73
Current Deferred Revenue	-0.24	-0.1	-0.04	-0.06	-0.26	-0.13		0.2	0.5	-0.1	-0.19	-0.1	-0.23	-0.53	-0.39	-0.11	-0.36	-0.13	-0.44	-0.07	-0.24	-0.49	-0.26	-0.97	-0.11	-0.21
Net Debt	-0.48	0.31	0.13	0.07	-0.6	-0.03	0.2		0.26	0.07	-1.0	0.12	-0.95	-0.58	-0.32	0.11	-0.42	0.02	-0.4	0.08	-0.93	-0.38	-0.29	-0.15	-0.2	-0.25
Retained Earnings	-0.87	-0.66	-0.72	-0.8	-0.84	-0.76	0.5	0.26		-0.83	-0.3	-0.77	-0.31	-0.44	-0.27	-0.78	-0.88	-0.79	-0.97	-0.8	-0.37	0.23	-0.94	-0.68	0.12	-0.83
Accounts Payable	0.82	0.92	0.97	1.0	0.73	0.9	-0.1	0.07	-0.83		-0.02	0.99	-0.03	0.01	-0.12	0.98	0.76	0.85	0.82	1.0	0.02	-0.68	0.92	0.35	-0.13	0.81
Cash	0.52	-0.27	-0.09	-0.02	0.63	0.08	-0.19	-1.0	-0.3	-0.02		-0.07	0.95	0.59	0.3	-0.06	0.46	0.01	0.44	-0.03	0.93	0.34	0.33	0.16	0.2	0.28
Non Current Assets Total	0.78	0.96	0.99	0.99	0.67	0.89	-0.1	0.12	-0.77	0.99	-0.07		-0.12	-0.04	-0.23	0.99	0.69	0.77	0.77	1.0	-0.07	-0.72	0.88	0.35	-0.03	0.73
Cash And Short Term Investments	0.53	-0.34	-0.15	-0.05	0.65	0.0	-0.23	-0.95	-0.31	-0.03	0.95	-0.12		0.56	0.49	-0.09	0.48	0.14	0.46	-0.06	0.99	0.43	0.33	0.18	-0.01	0.35
Net Receivables	0.33	-0.13	-0.11	0.0	0.4	0.24	-0.53	-0.58	-0.44	0.01	0.59	-0.04	0.56		0.48	0.02	0.48	0.08	0.42	0.01	0.58	0.39	0.29	0.49	-0.05	0.19
Common Stock Shares Outstanding	0.15	-0.3	-0.32	-0.17	0.23	-0.17	-0.39	-0.32	-0.27	-0.12	0.3	-0.23	0.49	0.48		-0.19	0.2	0.29	0.26	-0.18	0.53	0.49	0.11	0.31	-0.69	0.06
Non Current Liabilities Total	0.79	0.96	0.98	0.99	0.69	0.9	-0.11	0.11	-0.78	0.98	-0.06	0.99	-0.09	0.02	-0.19		0.7	0.77	0.78	0.99	-0.05	-0.71	0.89	0.36	-0.06	0.72
Inventory	0.91	0.5	0.66	0.74	0.9	0.8	-0.36	-0.42	-0.88	0.76	0.46	0.69	0.48	0.48	0.2	0.7		0.81	0.92	0.73	0.54	-0.19	0.91	0.51	-0.16	0.93
Other Current Assets	0.78	0.64	0.72	0.82	0.72	0.73	-0.13	0.02	-0.79	0.85	0.01	0.77	0.14	0.08	0.29	0.77	0.81		0.79	0.8	0.22	-0.44	0.84	0.32	-0.55	0.85
Other Stockholder Equity	0.96	0.62	0.73	0.81	0.94	0.75	-0.44	-0.4	-0.97	0.82	0.44	0.77	0.46	0.42	0.26	0.78	0.92	0.79		0.8	0.51	-0.23	0.97	0.61	-0.1	0.87
Total Liab	0.81	0.94	0.98	1.0	0.71	0.9	-0.07	0.08	-0.8	1.0	-0.03	1.0	-0.06	0.01	-0.18	0.99	0.73	0.8	0.8		-0.02	-0.71	0.91	0.32	-0.08	0.76
Total Current Assets	0.57	-0.3	-0.11	0.0	0.69	0.05	-0.24	-0.93	-0.37	0.02	0.93	-0.07	0.99	0.58	0.53	-0.05	0.54	0.22	0.51	-0.02		0.39	0.38	0.21	-0.07	0.41
Short Term Debt	-0.34	-0.75	-0.75	-0.71	-0.22	-0.59	-0.49	-0.38	0.23	-0.68	0.34	-0.72	0.43	0.39	0.49	-0.71	-0.19	-0.44	-0.23	-0.71	0.39		-0.44	0.29	0.07	-0.3
Common Stock	0.96	0.74	0.85	0.91	0.92	0.85	-0.26	-0.29	-0.94	0.92	0.33	0.88	0.33	0.29	0.11	0.89	0.91	0.84	0.97	0.91	0.38	-0.44		0.47	-0.12	0.88
Good Will	0.42	0.34	0.29	0.31	0.42	0.35	-0.97	-0.15	-0.68	0.35	0.16	0.35	0.18	0.49	0.31	0.36	0.51	0.32	0.61	0.32	0.21	0.29	0.47		0.09	0.39
Non Currrent Assets Other	-0.09	-0.01	0.03	-0.1	-0.08	-0.09	-0.11	-0.2	0.12	-0.13	0.2	-0.03	-0.01	-0.05	-0.69	-0.06	-0.16	-0.55	-0.1	-0.08	-0.07	0.07	-0.12	0.09		-0.13
Other Assets	0.86	0.54	0.71	0.78	0.84	0.73	-0.21	-0.25	-0.83	0.81	0.28	0.73	0.35	0.19	0.06	0.72	0.93	0.85	0.87	0.76	0.41	-0.3	0.88	0.39	-0.13

Click cells to compare fundamentals

Perspective Therapeutics Account Relationship Matchups

Perspective Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.7M	70.4M	64.4M	58.1M	97.9M	102.8M
Other Current Liab	(321K)	89K	1.0M	(406K)	9.5M	9.9M
Total Current Liabilities	1.6M	1.8M	2.3M	2.7M	15.7M	16.4M
Total Stockholder Equity	5.7M	67.4M	61.3M	54.6M	75.2M	78.9M
Property Plant And Equipment Net	2.7M	2.7M	2.5M	2.1M	6.3M	6.6M
Net Debt	(1.4M)	(63.1M)	(55.4M)	(21.0M)	(6.7M)	(7.0M)
Retained Earnings	(87.9M)	(91.3M)	(98.6M)	(105.9M)	(152.4M)	(160.1M)
Accounts Payable	654K	730K	966K	1.5M	6.1M	6.4M
Cash	2.4M	63.8M	55.9M	21.0M	9.2M	10.4M
Non Current Assets Total	3.2M	3.1M	5.1M	2.3M	81.1M	85.1M
Cash And Short Term Investments	2.4M	63.8M	55.9M	43.8M	9.2M	12.1M
Net Receivables	2.0M	2.0M	1.6M	1.4M	1.2M	986.9K
Common Stock Shares Outstanding	67.6M	103.8M	14.2M	142.1M	26.8M	34.7M
Liabilities And Stockholders Equity	8.7M	70.4M	64.4M	58.1M	97.9M	102.8M
Non Current Liabilities Total	621K	1.4M	1.2M	896K	7.0M	7.4M
Inventory	645K	980K	1.4M	1.4M	1.6M	1.7M
Other Current Assets	426K	481K	27K	6.7M	6.4M	6.7M
Other Stockholder Equity	93.6M	158.6M	159.7M	160.4M	227.3M	244.4M
Total Liab	3.0M	3.0M	3.2M	3.4M	22.7M	23.8M
Total Current Assets	5.5M	67.3M	59.3M	53.2M	16.8M	14.5M
Common Stock	55K	67K	69K	142K	282K	296.1K
Non Currrent Assets Other	137K	76K	2.5M	(2.3M)	182K	294.6K
Intangible Assets	138K	130K	107K	86K	50.4M	52.9M
Net Invested Capital	5.7M	67.4M	61.3M	76.9M	88.4M	48.6M
Net Working Capital	3.9M	65.5M	57.1M	1.2M	1.3M	1.3M
Property Plant And Equipment Gross	10.3M	10.0M	10.0M	7.0M	6.3M	5.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Perspective Stock Analysis

When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Perspective Book Value Per Share vs Free Cash Flow Yield Analysis

Book Value Per Share vs Free Cash Flow Yield

Book Value Per Share vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Book Value Per Share

Free Cash Flow Yield

Perspective Therapeutics fundamental ratios Correlations

Perspective Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Perspective Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Perspective Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Accounts Payable	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Accounts Payable
Total Liab	+ 1.0	Non Current Assets Total
Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Other Current Liab

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.97	Retained Earnings
Good Will	- 0.97	Current Deferred Revenue
Cash And Short Term Investments	- 0.95	Net Debt
Common Stock	- 0.94	Retained Earnings
Total Current Assets	- 0.93	Net Debt